Dimitry S.A. Nuyten, M.D., Ph.D., has been appointed chief medical officer, Aduro Biotech, Inc., a clinical stage biopharma company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways.

Dr. Nuyten joins the company from Pfizer where he most recently served as vice president and Immuno-Oncology Clinical Development Leader, overseeing the clinical strategy for BAVENCIO (avelumab), a human anti-programmed death ligand-1 (PD-L1) antibody, utomilumab, a human monoclonal antibody (mAb) agonist that selectively binds to 4-1BB and additional programs that included pivotal and exploratory trials with immuno-oncology combinations. Prior to Pfizer, he served as Group Medical Director and Exploratory Development Team Leader at Bristol-Myers Squibb, where he was responsible for the development of several early phase compounds in oncology.

“Dimitry’s expertise as a radiation oncologist specializing in cancer biology and his experience leading immuno-oncology clinical strategy and development will be instrumental to Aduro,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “We are extremely pleased to welcome Dimitry as we prepare to broaden our development plans for STING agonist ADU-S100 and initiate our first in human study of anti-APRIL antibody BION-1301 in IgA nephropathy.”